2.19
+0.015(+0.69%)
Currency In USD
| Previous Close | 2.17 |
| Open | 2.15 |
| Day High | 2.23 |
| Day Low | 2.12 |
| 52-Week High | 3.94 |
| 52-Week Low | 1.58 |
| Volume | 5.88M |
| Average Volume | 5.59M |
| Market Cap | 431.51M |
| PE | -3.27 |
| EPS | -0.67 |
| Moving Average 50 Days | 2.4 |
| Moving Average 200 Days | 2.24 |
| Change | 0.02 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $56.41 as of December 21, 2024 at a share price of $2.19. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $39.25 as of December 21, 2024 at a share price of $2.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
GlobeNewswire Inc.
Dec 18, 2024 12:00 PM GMT
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents $150 Million Strategic Investment Led by Healthcare Speci
Esperion Announces $210 Million Convertible Debt Financing
GlobeNewswire Inc.
Dec 13, 2024 11:00 AM GMT
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
GlobeNewswire Inc.
Dec 12, 2024 1:00 PM GMT
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – AN